Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor
Rong Hu, Wanli Wang, Ying-Yue Yang, Xia-Tong Hu, Qiwei Wang, Weiqiong Zuo, Ying Xu, Qiang Feng, Ningyu Wang
Topics & Concepts
Prostate cancerChemistryCancer researchBRD4PLK1Cell cycleIn vivoCell growthProtein degradationCancerApoptosisCell cycle checkpointPharmacologyBiochemistryBiologyInternal medicineMedicineBromodomainGeneAcetylationBiotechnologyProtein Degradation and InhibitorsUbiquitin and proteasome pathwaysMultiple Myeloma Research and Treatments